NNE Pharmaplan was the company responsible for the orchestration of all the qualification processes required during the expansion project, which ran from September 2005 to September 2008. Rentschler’s main customers are Maxygen (novel factor VIIa protein) and Roche. It invested €70m in the facility prior to 2002.ĭr Nikolaus F Rentschler, CEO at Rentschler Biotechnologie, commented: “By expanding our production capacity we will establish Rentschler Biotechnologie as a market supplier of antibodies”. The company is now responding to demand for manufacturing capacity in the biotech sector by carrying out a major expansion project. It was also the first company in the world to obtain authorisation for an interferon type drug. The company employs 350 personnel and is primarily engaged in development, clinical testing, production, fill and finish, and analysis of proteins for human therapeutic or diagnostic use according to international standards. The company has been involved in the industry for over 30 years and provides a full range of services for development, production and approval of biopharmaceuticals in compliance with good manufacturing practice (GMP). Rentschler Biotechnologie GmbH is a full-service contract manufacturer and part of the Rentschler Group based in Laupheim, Germany.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |